RT Journal Article
T1 EVALUATION OF DOCETAXEL USE IN NON-SMALL CELL LUNG CANCER: REAL-WORLD HEALTH OUTCOMES
A1 Merino Almazan, Macarena
A1 Marin Pozo, Juan Francisco
A1 Duarte Perez, Juan Manuel
K1 docetaxel
K1 non-small cell lung cancer
K1 real-world data
K1 nintedanib
K1 Nintedanib
K1 Nivolumab
K1 Phase-3
AB Chemotherapy agents such as docetaxel are still used after failure of first or second-line immunotherapy. In order to establish the ideal choice of treatment, it is necessary to compare the efficacy and safety in the real-world setting between the available schemes. We performed a retrospective, observational study in a referral hospital including patients treated with docetaxel for non-small cell lung cancer between January 2013 and June 2017. Effectiveness variables included overall survival (OS) and progression free survival (PFS). The safety variable was the incidence of adverse events (AE). 91 patients were enrolled (84.6% men) with a mean age of 63.6 years. 21 patients were treated with a combination of docetaxel + nintedanib, and the rest with monotherapy. 79.1% of patients presented AEs of any grade and treatment had to be delayed or discontinued in 10%. The median PFS was 2.8 months (95% CI 2.3-3.3) and for OS, 6.9 months (95% CI 4.9-8.8). In adenocarcinoma patients no difference in OS was observed between monotherapy with docetaxel vs. docetaxel + nintedanib. Overall results are similar to clinical trials, but not when nintedanib is added to the therapy.
PB Soc stiinte farmaceutice romania
SN 0014-8237
YR 2021
FD 2021-05-01
LK http://hdl.handle.net/10668/19495
UL http://hdl.handle.net/10668/19495
LA en
DS RISalud
RD Apr 20, 2025